Last updated on July 2019

An Observational Study of Kadcyla Safety in Breast Cancer


Brief description of study

This is a phase IV, prospective, multicenter, non-interventional study (regulatory post-marketing surveillance) in approximately 3,000 patients who are to receive Kadcyla (trastuzumab emtansine). Patients with HER2-positive, unresectable locally advanced or metastatic breast cancer, who have received prior treatment with trastuzumab and a taxane, and administered Kadcyla infusion at physician's discretion will be registered for this surveillance in Korea. Patients will be asked to provide informed consent; data will be collected by electronic Case Report Forms for approximately 6 years.

Clinical Study Identifier: NCT02305641

Find a site near you

Start Over

Gangnam Severance Hospital

Seoul, Korea, Republic of
1.92miles
  Connect »

Ewha Womans University Mokdong Hospital

Seoul, Korea, Republic of
1.92miles
  Connect »

Korea University Anam Hospital

Seoul, Korea, Republic of
4.3miles
  Connect »

Kangbuk Samsung Hospital

Seoul, Korea, Republic of
4.3miles
  Connect »

SMG-SNU Boramae Medical Center

Seoul, Korea, Republic of
4.3miles
  Connect »

ChungAng University Hospital

Seoul, Korea, Republic of
4.3miles
  Connect »

Yeouido St. Mary's Hospital

Seoul, Korea, Republic of
4.3miles
  Connect »

Konkuk University Medical Center

Seoul, Korea, Republic of
4.3miles
  Connect »

Asan Medical Center - Oncology

Seoul, Korea, Republic of
4.3miles
  Connect »

Samsung Medical Center

Seoul, Korea, Republic of
4.3miles
  Connect »

Seoul National University Hospital

Seoul, Korea, Republic of
5.65miles
  Connect »